ReviewThe use of scintigraphic imaging as a tool in the development of liposome formulations
Introduction
Scintigraphic imaging is proving to be a valuable tool for the development of liposome-based therapeutic agents. In particular, this imaging modality can be used in the following areas: (1) tracking the distribution of liposomes in the body; (2) monitoring of therapeutic responses following the administration of liposome-encapsulated pharmaceuticals; and (3) investigating the physiological responses associated with liposome administration.
Scintigraphic imaging provides the ability to non-invasively track and quantitate the distribution of liposomes in the body using a gamma-emitting radionuclide label. A particular advantage of this imaging modality is that scintigraphy requires only a small amount of actual matter (usually in the nanogram range), which does not interfere with either the biodistribution of the labeled liposome or the physiological processes involved in its distribution. Other imaging modalities, such as magnetic resonance imaging (MRI) and computer tomographic imaging (CT), provide higher resolution images than scintigraphy, but require the administration of a significantly higher amount of matter to achieve image contrast (milligrams for MRI and grams for CT) [1]. The greater amount of contrast material required with these other imaging modalities can alter the normal biodistribution of the agent being tracked as well as increase the risk for an adverse reaction induced by the contrast agent. To date, clinicians have generally utilized MRI and CT contrast agents to demonstrate changes in vascular permeability and blood flow. On the other hand, scintigraphic imaging has been used to depict a wide variety of physiological processes, ranging from changes in glucose, protein and fatty acid metabolism to the demonstration of gene expression and detection of changes in the concentration of cell signaling receptors [2], [3], [4], [5], [6].
In particular, scintigraphic imaging has the following advantages for liposome research compared to other imaging modalities: (1) the total organism can be imaged in a single whole body scan; (2) a time course of the movement of a radionuclide agent can be easily obtained by acquiring images at varying time points after administration of the radiolabeled agent; (3) scintigraphic imaging methods are inherently quantitative since each scintillation is recorded and scanned into an image matrix for assembly of the visual image; and (4) multiple agents can be tracked simultaneously in the same organism. The radionuclides typically used in scintigraphic imaging have energies ranging from 70 keV to 511 keV. Thus, with careful selection of the radionuclides so that there is an adequate separation of photon energies, several radiolabeled agents can be tracked simultaneously in the same organism. For example, the liposome vehicle labeled with one radionuclide can be tracked simultaneously with the encapsulated drug labeled with a different radionuclide.
Section snippets
Radioisotopes and procedures used for scintigraphic imaging
There are two classes of radioisotopes available for scintigraphic imaging: single photon radioisotopes and positron-emitting radioisotopes. Methods to label liposomes with both classes of radioisotopes are under investigation. The procedures used to perform an imaging study with each class of radioisotope are also outlined in this section.
Liposome labeling methods for use with scintigraphic imaging
Many methods have been developed for labeling liposomes with gamma-emitting radionuclides for use in scintigraphic imaging [11], [12]. Although radioisotopes can simply be encapsulated within liposomes, this type of labeling protocol is generally not practical due to the requirement of rapid liposome manufacture and imaging within a short time period. This is particularly true with radioisotopes with decay half-lives under 24 h, which includes 99mTc and 18F. A better approach is the labeling of
Some examples of the application of scintigraphic imaging during liposome drug development
As described in Section 1, scintigraphic imaging can be a very beneficial tool during liposome drug development. This section describes some specific examples where scintigraphic imaging was helpful in: (1) determining the optimal lipid formulation for a particular liposome drug application; (2) determining potential clinical indications for a particular liposome drug; and (3) deciding the optimal time for the delivery of a liposomal anti-cancer drug when used in combination with other therapy
Use of scintigraphic imaging in the study of the immune response to liposomes
Scintigraphic imaging studies have lead to unexpected insights regarding the interaction of liposomes with the immune system. For example, during clinical trials of 99mTc-PEG-liposomes as an infection/inflammation imaging agent by Dams et al. as previously described in Section 4.3, patients were administered a low diagnostic dose of liposomes which was only 1/20th of the lipid dose of a standard therapeutic liposome-based pharmaceutical. Unexpectedly, despite the low lipid dose used in this
Human scintigraphic imaging for studies of drug delivery
Human scintigraphic studies of new therapeutic liposome formulations labeled with radionuclides will be useful for determining what percentage of the drug formulation actually reaches the therapeutic site. The therapeutic success, or lack thereof, of a particular liposome formulation can then be predicted in each individual patient. If there is no significant uptake of liposomes in the disease process, the likelihood of therapeutic success will be diminished. Altered biodistribution in
Summary
Scintigraphic imaging is an ideal modality for use in the development of liposome-encapsulated pharmaceuticals. These imaging studies are useful for formulation development in the pre clinical stages and for the non-invasive monitoring of patients in clinical trials.
Scintigraphic imaging has the potential to provide new medical insights that will further the development of liposome-encapsulated pharmaceuticals.
Acknowledgements
The authors thank Robert Klipper for the skilled assistance with the animal experiments and for providing the schematic diagram shown in Fig. 1; and Sandy Solano for preparation of this manuscript. The authors would also like to thank Dr. Don Thrall, North Carolina State University, for providing the images depicted in Fig. 5 and Dr. Peter Laverman, University Hospital, Nijmegen, The Netherlands, for providing the images depicted in Fig. 6, Fig. 7.
References (106)
- et al.
Int J Rad Appl Instrum B
(1992) - et al.
Adv Drug Deliv Rev.
(1999) Adv Drug Delivery Rev.
(1999)- et al.
Nucl Med Biol.
(1992) Advanced Drug Delivery Reviews
(1999)- et al.
Biochim Biophys Acta
(1984) - et al.
Nucl Med Biol.
(1992) - et al.
Methods Enzymol.
(1987) - et al.
FEBS Letters
(1990) - et al.
Biochim Biophys Acta
(1991)
Biochim Biophys Acta
Lancet
Adv Drug Delivery Rev.
FEBS Letters
Prog Biophys Mol Biol.
Biochim Biophys Acta
Biochim Biophys Acta
Vaccine
Cell Immunol.
Semin Nucl Med.
Surgery
Life Sci.
Biochim Biophys Acta
J Controlled Release
Semin Nucl Med.
Biochim Biophys Acta
Arch Biochem Biophys
Oncologist
Adv Neurol.
J Neurosci Res.
Med Phys
J Nucl Med.
J. Nucl. Med.
J Liposome Res.
J Nucl Med.
Med Res Rev.
Proc Natl Acad Sci USA
J Drug Target
Br J Cancer
Artif Cells Blood Substit Immobil Biotechnol
J Nucl Med.
J Pharmacol Exp Ther.
Lab Invest.
Cancer Res.
Br J Cancer
Cited by (47)
Radiation sterilization of liposomes: A literature review
2024, Radiation Physics and ChemistryStructural characterization of novel cationic diC16-amidine bilayers: Evidence for partial interdigitation
2015, Biochimica et Biophysica Acta - BiomembranesCitation Excerpt :Over a dozen of liposome formulations have been approved for human use [2], offering suitable treatment for a series of diseases such as fungal infections [3,4], leishmaniasis [5], macular degeneration [6] and cancer [7–9]. They have also been employed in vaccine [10–12] and imaging [13,14] applications. This has prompted the development and characterization of new synthetic lipids, like cationic lipids [15,16].
Radiolabeled porous silicon for bioimaging applications
2014, Porous Silicon for Biomedical ApplicationsLiposomal drug delivery systems: From concept to clinical applications
2013, Advanced Drug Delivery ReviewsCitation Excerpt :Some of their work is described in detail in other papers in this 25th anniversary volume. We have not covered several large areas of liposomal research, including vaccines [1,2], imaging [3,4], and applications in cosmetics and cosmeceuticals [5,6]. The reader is directed to the cited excellent recent reviews.
Liposome imaging agents in personalized medicine
2012, Advanced Drug Delivery ReviewsCitation Excerpt :Remote loading is an active loading of the radionuclide into the aqueous phase of liposomes, where an ionophore or a lipophilic chelator transports the radionuclide over the membrane of preformed liposomes, and the radionuclide is delivered to a pre-encapsulated chelator (Fig. 2). The remote loading approach concentrates radionuclides in the internal aqueous compartment of the liposomes providing high loading efficiencies (> 90%), and seems to provide the greatest in vivo stability, because of the protected location which prevents exchange of the radionuclide with the biological environment [33]. For the remote loading approach to be successful with high loading efficiency and radionuclide retention, a higher affinity of the radionuclide for the entrapped chelator compared to the lipophilic chelator is required [63].
<sup>64</sup>Cu loaded liposomes as positron emission tomography imaging agents
2011, BiomaterialsCitation Excerpt :To date, remote loading approaches have been developed with different lipophilic transporters (ionophores), e.g. oxine [20], A23187 (calcimycin) [21] and hexamethylpropylene amine oxime (HMPAO) [22] to load preformed liposomes with 111ln, 177Lu, 99mTc and 67Ga, radioisotopes for SPECT applications. However, no remote loading of positron-emitters into liposomes has been reported even though the value of such imaging agents has been described in multiple papers [23,24]. The goal of this study was to develop an efficient remote loading of the PET radionuclide 64Cu into liposomes.